Khan MS, Stamp E, Sammon C, Brabander T, de Herder WW, Pavel ME (2021)
Publication Type: Journal article
Publication year: 2021
Book Volume: 16
Pages Range: 5-13
DOI: 10.1016/j.ejcsup.2021.06.002
Head-to-head comparisons of the efficacy of treatments for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have not yet been reported. This study used a series of matching-adjusted indirect comparisons to indirectly compare the effectiveness of [177Lu]Lu-DOTA-TATE to everolimus, sunitinib and best supportive care (BSC) for extending progression-free survival and overall survival in patients with advanced, unresectable gastrointestinal (GI)-NETs and P-NETs. The results of the main analysis suggest that after accounting for differences in key prognostic variables, the hazard of progression was 62% (hazard ratio [HR], 0.38; confidence interval [CI]
APA:
Khan, M.S., Stamp, E., Sammon, C., Brabander, T., de Herder, W.W., & Pavel, M.E. (2021). Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours. Ejc Supplements, 16, 5-13. https://doi.org/10.1016/j.ejcsup.2021.06.002
MLA:
Khan, Mohid S., et al. "Matching-adjusted indirect treatment comparison of [177Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [177Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours." Ejc Supplements 16 (2021): 5-13.
BibTeX: Download